MedPath

Apollomics

🇭🇰Hong Kong, China
Ownership
-
Employees
45
Market Cap
-
Website
Introduction

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.

Clinical Trials

7

Active:2
Completed:1

Trial Phases

3 Phases

Phase 1:5
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 2
1 (14.3%)
Phase 3
1 (14.3%)

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Phase 1
Conditions
Bioequivalence
Interventions
First Posted Date
2022-05-10
Last Posted Date
2022-06-15
Lead Sponsor
Apollomics Inc.
Target Recruit Count
48
Registration Number
NCT05367388
Locations
🇳🇿

New Zealand Clinical Research, Auckland, New Zealand

APL-102 Capsule in Patients With Advanced Solid Tumors

Phase 1
Suspended
Conditions
Advanced Solid Tumor
Interventions
Drug: APL-102 Capsules
First Posted Date
2021-09-24
Last Posted Date
2025-06-27
Lead Sponsor
Apollomics Inc.
Target Recruit Count
30
Registration Number
NCT05055518
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Phase 3
Terminated
Conditions
Relapsed/Refractory AML
Interventions
Drug: Placebo
First Posted Date
2021-09-23
Last Posted Date
2025-06-27
Lead Sponsor
Apollomics Inc.
Target Recruit Count
140
Registration Number
NCT05054543
Locations
🇨🇳

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China

🇨🇳

The First Affiliated Hospital of Zhejiang University, Hangzhou, China

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Phase 1
Completed
Conditions
Relapsed/Refractory AML
Interventions
First Posted Date
2021-04-09
Last Posted Date
2025-06-27
Lead Sponsor
Apollomics Inc.
Target Recruit Count
12
Registration Number
NCT04839341
Locations
🇨🇳

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China

🇨🇳

The First Affiliated Hospital of Zhejiang University, Hangzhou, China

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Phase 2
Recruiting
Conditions
Gastroesophageal Junction Adenocarcinoma
NSCLC
Lung Cancer
Brain Tumor
Glioblastoma Multiforme
EGFR Gene Mutation
Solid Tumors
Advanced Cancer
Renal Cancer
MET Alteration
Interventions
Drug: APL-101 Oral Capsules
First Posted Date
2017-06-05
Last Posted Date
2025-06-27
Lead Sponsor
Apollomics Inc.
Target Recruit Count
497
Registration Number
NCT03175224
Locations
🇭🇺

Komarom-Esztergom Varmegyei Szent Borbala Korhaz, Tatabanya, Hungary

🇺🇸

Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

🇺🇸

Moffitt, Tampa, Florida, United States

and more 32 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.